Q1 EPS Estimate for Aytu BioPharma Lowered by Analyst

Aytu BioPharma Inc. (NASDAQ:AYTU) – Ascendiant Capital Markets cut their Q1 2027 earnings estimates for shares of Aytu BioPharma in a report released on Tuesday, September 29th. Ascendiant Capital Markets analyst E. Woo now expects that the company will earn ($0.10) per share for the quarter, down from their prior estimate of ($0.01). Ascendiant Capital Markets currently has a “Buy” rating and a $14.50 target price on the stock. The consensus estimate for Aytu BioPharma’s current full-year earnings is ($0.16) per share. Ascendiant Capital Markets also issued estimates for Aytu BioPharma’s Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at $0.06 EPS and FY2027 earnings at ($0.16) EPS.

Several other research analysts also recently commented on the company. Zacks Research downgraded Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Monday. Citigroup restated a “positive” rating on shares of Aytu BioPharma in a report on Tuesday, September 22nd. Finally, Weiss Ratings upgraded Aytu BioPharma from a “sell (d-)” rating to a “sell (d)” rating in a research report on Tuesday, September 22nd. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $14.50.

Aytu BioPharma Stock Performance

NASDAQ AYTU opened at $2.05 on Tuesday. The company has a 50-day simple moving average of $2.22 and a two-hundred day simple moving average of $2.30. The company has a quick ratio of 1.00, a current ratio of 1.13 and a debt-to-equity ratio of 0.26. Aytu BioPharma has a 12-month low of $1.80 and a 12-month high of $3.07. The firm has a market cap of $22.28 million, a price-to-earnings ratio of -1.23 and a beta of 0.17.

Hedge Funds Weigh In On Aytu BioPharma

A number of institutional investors have recently added to or reduced their stakes in AYTU. BlackRock Inc. bought a new position in shares of Aytu BioPharma in the 2nd quarter worth about $49,000. Persistent Asset Partners Ltd bought a new stake in Aytu BioPharma during the second quarter worth about $82,000. Dimensional Fund Advisors LP boosted its stake in Aytu BioPharma by 23.3% during the first quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock worth $119,000 after acquiring an additional 8,222 shares in the last quarter. Arete Wealth Advisors LLC purchased a new stake in Aytu BioPharma in the first quarter worth about $135,000. Finally, Crown Advisors Management Inc. purchased a new stake in Aytu BioPharma in the second quarter worth about $430,000. Institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on developing and commercializing prescription medicines for pediatric and primary-care markets. The company’s portfolio includes treatments for attention-deficit/hyperactivity disorder (ADHD), along with products addressing allergies, respiratory conditions, and other common health needs.

Aytu’s ADHD portfolio has included orally disintegrating and liquid formulations designed for children and adolescents, such as Adzenys XR-ODT, Cotempla XR-ODT, and Dyanavel XR.